Ipilimumab-associated colitis or refractory Clostridium difficile infection?

BMJ Case Reports

Volumn 2015, Issue , 2015, Pages

  Gupta, Arjun ^a   Khanna, Sahil ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; LOPERAMIDE; MEPREDNISONE; METRONIDAZOLE; NIVOLUMAB; PREDNISONE; RITUXIMAB; STEROID; VANCOMYCIN; ANTIINFLAMMATORY AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG USE; FECES MICROBIOTA TRANSPLANTATION; FEMALE; FLUID RESUSCITATION; FOLLOW UP; HUMAN; MEDICAL HISTORY; MEDICAL PROCEDURES; METASTATIC MELANOMA; NONHODGKIN LYMPHOMA; PATIENT REFERRAL; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT OUTCOME; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUID THERAPY; MALE; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CLOSTRIDIUM DIFFICILE; COLITIS; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUID THERAPY; HUMANS; MALE; METHYLPREDNISOLONE; TREATMENT OUTCOME;

EID: 84939222301     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2015-211160     Document Type: Article

References (19)

1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198-208.
2. Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist 2014;7:63-72.
3. Gupta A, Patel R, Baddour LM, et al. Extraintestinal Clostridium difficile infections: a single-center experience. Mayo Clin Proc 2014;89:1525-36.
4. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53:994-1002.
5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
6. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9.
7. Khanna S, Pardi DS. Clostridium difficile infection: management strategies for a difficult disease. Therap Adv Gastroenterol 2014;7:72-86.
8. De Felice KM, Gupta A, Rakshit S, et al. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res 2015.
9. Gupta A, De Felice KM, Loftus Jr EV, et al. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015; in press.
10. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 2010;4:409-16.
11. Chopra T, Alangaden GJ, Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 2010;8:1113-19.
12. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
13. Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol 2014;11:91-9.
14. Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2015;21:712-20.
15. McCutcheon JL, McClainb CM, Puzanovc I, et al. Infectious colitis associated with ipilimumab therapy. Gastroenterol Res 2014;7:28-31.
16. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. US DEPARTMENT OF HEALTH AND HUMAN SERVICES. National Institutes of Health. National Cancer Institute [cited 28 May 2009 (v4.03: 14 June, 2010)]. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5×11.pdf
17. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010;10:11.
18. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009;54:2538-40.
19. Babi C, Jaclyn S, Mark N, John H, et al. Ipilimumab induced enterocolitis: a fatal immune-related adverse event of melanoma treatment. J Gastroenterol Hepatol Res 2013;2:934-6.